RAD51B and female reproductive organ cancer: RAD51B was altered in 3.6% (38/1055) of uterus leiomyosarcoma samples, lower than the previously reported RAD51B alteration prevalence of 7.4% (16/216)71 and 12.4% (13/105)72.